Pharmaceutical

Lorcaserin hydrochloride by EpyGenix Therapeutics for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy): Likelihood of Approval

Lorcaserin hydrochloride is under clinical development by EpyGenix Therapeutics and currently in Phase I for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy).

Apr 23, 2024 - 00:00
Lorcaserin hydrochloride is under clinical development by EpyGenix Therapeutics and currently in Phase I for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy).
Read the original article

Tags:

Previous Article

AlphaMedix by Orano Med for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NE...

Next Article

Datopotamab deruxtecan by Daiichi Sankyo for Metastatic Adenocarcinoma of The Pa...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

MHRA agrees licence change for Pfizer-BioNTech’s Comirnaty vaccine

MHRA agrees licence change for Pfizer-BioNTech’s Comirn...

Feb 12, 2024

Cancer Research UK and CRIS fund lung cancer vaccine research

Cancer Research UK and CRIS fund lung cancer vaccine re...

Mar 26, 2024

Casgevy: Launch sequence and price analysis of the first marketed CRISPR therapy

Casgevy: Launch sequence and price analysis of the firs...

Aug 3, 2024